Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
JCI Insight ; 6(8)2021 04 22.
Article in English | MEDLINE | ID: mdl-33755599

ABSTRACT

Sphingosine-1-phosphate lyase insufficiency syndrome (SPLIS) is a rare metabolic disorder caused by inactivating mutations in sphingosine-1-phosphate lyase 1 (SGPL1), which is required for the final step of sphingolipid metabolism. SPLIS features include steroid-resistant nephrotic syndrome and impairment of neurological, endocrine, and hematopoietic systems. Many affected individuals die within the first 2 years. No targeted therapy for SPLIS is available. We hypothesized that SGPL1 gene replacement would address the root cause of SPLIS, thereby serving as a universal treatment for the condition. As proof of concept, we evaluated the efficacy of adeno-associated virus 9-mediated transfer of human SGPL1 (AAV-SPL) given to newborn Sgpl1-KO mice that model SPLIS and die in the first weeks of life. Treatment dramatically prolonged survival and prevented nephrosis, neurodevelopmental delay, anemia, and hypercholesterolemia. STAT3 pathway activation and elevated proinflammatory and profibrogenic cytokines observed in KO kidneys were attenuated by treatment. Plasma and tissue sphingolipids were reduced in treated compared with untreated KO pups. SGPL1 expression and activity were measurable for at least 40 weeks. In summary, early AAV-SPL treatment prevents nephrosis, lipidosis, and neurological impairment in a mouse model of SPLIS. Our results suggest that SGPL1 gene replacement holds promise as a durable and universal targeted treatment for SPLIS.


Subject(s)
Aldehyde-Lyases/genetics , Gene Transfer Techniques , Metabolism, Inborn Errors/genetics , Nephrotic Syndrome/genetics , Neurodevelopmental Disorders/genetics , Anemia/genetics , Anemia/metabolism , Anemia/physiopathology , Animals , Cytokines/metabolism , Dependovirus , Genetic Therapy , Humans , Hypercholesterolemia/genetics , Hypercholesterolemia/metabolism , Hypercholesterolemia/physiopathology , Inflammation/metabolism , Kidney/metabolism , Metabolism, Inborn Errors/metabolism , Metabolism, Inborn Errors/physiopathology , Metabolism, Inborn Errors/therapy , Mice , Mice, Knockout , Nephrotic Syndrome/metabolism , Nephrotic Syndrome/physiopathology , Neurodevelopmental Disorders/metabolism , Neurodevelopmental Disorders/physiopathology , STAT3 Transcription Factor/metabolism , Signal Transduction , Survival Rate
2.
Biochem Pharmacol ; 86(1): 43-55, 2013 Jul 01.
Article in English | MEDLINE | ID: mdl-23500538

ABSTRACT

In this study the sterol and oxysterol profile of newborn brain from the Dhcr7(Δ3-5/T93M) mouse model of Smith-Lemli-Opitz syndrome (SLOS) has been investigated. This is a viable mouse model which is compound heterozygous containing one null allele and one T93M mutation on Dhcr7. We find the SLOS mouse has reduced levels of cholesterol and desmosterol and increased levels of 7- and 8-dehydrocholesterol and of 7- and 8-dehydrodesmosterol in brain compared to the wild type. The profile of enzymatically formed oxysterols in the SLOS mouse resembles that in the wild type but the level of 24S-hydroxycholesterol, the dominating cholesterol metabolite, is reduced in a similar proportion to that of cholesterol. A number of oxysterols abundant in the SLOS mouse are probably derived from 7-dehydrocholesterol, however, the mechanism of their formation is unclear.


Subject(s)
Oxidoreductases Acting on CH-CH Group Donors/genetics , Smith-Lemli-Opitz Syndrome/metabolism , Sterols/metabolism , Animals , Animals, Newborn , Cholesterol/metabolism , Chromatography, Liquid , Desmosterol/metabolism , Gene Knock-In Techniques , Mice , Mice, Mutant Strains , Oxidation-Reduction , Smith-Lemli-Opitz Syndrome/genetics , Spectrometry, Mass, Electrospray Ionization
3.
J Lipid Res ; 53(11): 2469-83, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22891291

ABSTRACT

Unesterified cholesterol is a major component of plasma membranes. In the brain of the adult, it is mostly found in myelin sheaths, where it plays a major architectural role. In the newborn mouse, little myelination of neurons has occurred, and much of this sterol comprises a metabolically active pool. In the current study, we have accessed this metabolically active pool and, using LC/MS, have identified cholesterol precursors and metabolites. Although desmosterol and 24S-hydroxycholesterol represent the major precursor and metabolite, respectively, other steroids, including the oxysterols 22-oxocholesterol, 22R-hydroxycholesterol, 20R,22R-dihydroxycholesterol, and the C(21)-neurosteroid progesterone, were identified. 24S,25-epoxycholesterol formed in parallel to cholesterol was also found to be a major sterol in newborn brain. Like 24S- and 22R-hydroxycholesterols, and also desmosterol, 24S,25-epoxycholesterol is a ligand to the liver X receptors, which are expressed in brain. The desmosterol metabolites (24Z),26-, (24E),26-, and 7α-hydroxydesmosterol were identified in brain for the first time.


Subject(s)
Chromatography, Liquid/methods , Mass Spectrometry/methods , Sterols/analysis , Animals , Animals, Newborn , Cholesterol/analysis , Desmosterol/analysis , Hydroxycholesterols/analysis , Mice
4.
Steroids ; 72(11-12): 802-8, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17714750

ABSTRACT

Smith-Lemli-Opitz syndrome (SLOS) is caused by deficiency in the terminal step of cholesterol biosynthesis, which is catalyzed by 7-dehydrocholesterol reductase (DHCR7). The disorder exhibits several phenotypic traits including dysmorphia and mental retardation with a broad range of severity. Pathogenesis of SLOS is complex due to multiple roles of cholesterol and may be further complicated by unknown effects of aberrant metabolites that arise when 7-dehydrocholesterol (7-DHC), the substrate for DHCR7, accumulates. A viable mouse model for SLOS has recently been developed, and here we characterize cholesterol metabolism in this model with emphasis on changes during the first few weeks of postnatal development. Cholesterol and 7-DHC were measured in "SLOS" mice and compared with measurements in normal mice. SLOS mice had measurable levels of 7-DHC at all ages tested (up to 1 year), while 7-DHC was below the threshold for detection in normal mice. In perinatal to weaning age SLOS mice, cholesterol and 7-DHC levels changed dramatically. Changes in brain and liver were independent; in brain cholesterol increased several fold while 7-DHC remained relatively constant, but in liver cholesterol first increased then decreased again while 7-DHC first decreased then increased. In older SLOS animals the ratio of 7-DHC/cholesterol, which is an index of biochemical severity, tended to approach, but not reach, normal. While these mice provide the best available genetic animal model for the study of SLOS pathogenesis and treatment, they probably will be most useful at early ages when the metabolic effects of the mutations are most dramatic. To correlate any experimental treatment with improved sterol metabolism will require age-matched controls. Finally, determining the mechanism by which these "SLOS" mice tend to normalize may provide insight into the future development of therapy.


Subject(s)
Aging/metabolism , Animals, Newborn/metabolism , Cholesterol/biosynthesis , Disease Models, Animal , Oxidoreductases Acting on CH-CH Group Donors/deficiency , Smith-Lemli-Opitz Syndrome/metabolism , Animals , Brain/enzymology , Liver/enzymology , Mice , Smith-Lemli-Opitz Syndrome/enzymology , Tissue Extracts
5.
Mol Ther ; 5(5 Pt 1): 617-26, 2002 May.
Article in English | MEDLINE | ID: mdl-11991753

ABSTRACT

Previous treatment of mucopolysaccharidosis type VII mice (Sly syndrome) with AAV vectors has resulted in increased levels of beta-glucuronidase (GUS) enzyme in some tissues with reduction of glycosaminoglycan storage granules and improved health. By adding coding sequences for secretion (Igkappa) and uptake (HIV-1 TAT) signals to the GUS gene delivered by AAV, and treating mice both intrathecally and intravenously as newborns, we have increased the GUS enzyme levels in more tissues and have improved the health of the mice so much that they are able to breed. The levels of GUS in the serum were above normal in some mice, which caused reduction of storage in the spleen, a nontransduced tissue. The heart and aorta showed therapeutic levels of GUS enzyme. AAV GUS DNA was found in brain and liver, which showed no storage. Phenotypically the treated mice were more active and showed less stunted skeletal growth. The pups born to these mice were not affected by the gene therapy, as shown by mutant levels of GUS enzyme in their tissues and the absence of AAV GUS DNA. However, they were resistant to intravenous treatment with AAV GUS due to the mother's antibodies, but not to intrathecal treatment.


Subject(s)
Animals, Newborn/physiology , Dependovirus/genetics , Genetic Therapy/methods , Glucuronidase/genetics , Glucuronidase/metabolism , Mucopolysaccharidosis VII/therapy , Animals , Animals, Newborn/virology , Blotting, Southern , Brain/enzymology , Brain/pathology , DNA Primers/chemistry , Gene Expression , Gene Transfer Techniques , Genetic Vectors , Heterozygote , Homozygote , Humans , Liver/enzymology , Liver/pathology , Mice , Mice, Inbred C57BL , Mice, Knockout , Mice, Transgenic , Mucopolysaccharidosis VII/enzymology , Reverse Transcriptase Polymerase Chain Reaction , Spleen/enzymology , Spleen/pathology , Tissue Distribution
SELECTION OF CITATIONS
SEARCH DETAIL
...